BIIB Biogen Inc.
Healthcare$193.08-0.35%ClosedMarket Cap: $28.51B
As of 2026-05-26
Valuation
P/E (TTM)
19.63
PEG
—
P/B
1.53
P/S
2.90
EV/EBITDA
11.40
DCF Value
$658.35
FCF Yield
9.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.8%
Operating Margin
15.6%
Net Margin
13.9%
ROE
7.5%
ROA
4.7%
ROIC
5.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.48B | 73.3% | $397.4M | $319.5M | $— | — |
| Q4 null | $2.28B | 78.2% | $-57.0M | $-48.4M | $— | — |
| FY null | $9.81B | 70.5% | $1.88B | $1.29B | $— | — |
| Q3 null | $2.45B | 64.3% | $613.8M | $466.5M | $— | — |
| Q2 null | $2.65B | 64.2% | $588.1M | $634.8M | $— | — |
| Q1 null | $2.43B | 76.2% | $732.6M | $240.5M | $— | — |
| Q4 null | $2.45B | 76.2% | $509.0M | $266.7M | $— | — |
| FY null | $9.68B | 76.1% | $2.49B | $1.63B | $— | — |
| Q3 null | $2.47B | 74.1% | $577.2M | $388.5M | $— | — |
| Q2 null | $2.46B | 61.2% | $366.5M | $583.6M | $— | — |
| Q1 null | $2.29B | 78.3% | $690.4M | $393.4M | $— | — |
| Q4 2023 | $2.39B | 74.1% | $512.4M | $249.7M | $1.71 | — |